| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94f3b8412f6df2247cdf3667fb19458f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-382
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2018-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f3f932fdce624969815902d477b3106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1850e6c1091c1cc20a5c90b30b392627 |
| publicationDate |
2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018133179-A1 |
| titleOfInvention |
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| abstract |
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10231944-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874628-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786555-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10213401-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11648222-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10881628-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517843-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10532073-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874694-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940127-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779558-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471030-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10485775-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874627-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11737996-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10363272-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11648223-B2 |
| priorityDate |
2016-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |